ReviewFrontiers in oncology2023
Clinical considerations of CDK4/6 inhibitors in HER2 positive breast cancer.
Cui Zhang et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
6 papers cite it
this papercites it
ReviewFrontiers in oncology2023
Cui Zhang et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.